Powering how Americans save, spend, and invest in health Copyright © 2026 HealthEquity, Inc. All rights reserved. | HealthEquity does not provide legal, tax or financial advice. Investor presentation 1 #1 HSA provider 1 in 4 HSAs in the US are with us +100k clients 200+ Network partners 10.1M HSAs +6% YoY $34.4B HSA assets +15% YoY 17.3M Total Accounts +5% YoY Source: HealthEquity key metrics reported as of Oct 31, 2025. #1 HSA by number of accounts based on 2025 Midyear Devenir HSA report, October 9, 2025. ...

Danaher Corporation Rainer Blair, President & CEO J.P. Morgan Healthcare Conference | January 13, 2026 Innovation at the speed of life. Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher's estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward looking" statements within the meaning of the federal secu ...

Alkermes 2026: Driving Profitable Growth in Neuroscience and Leading Orexin Innovation January 2026 Forward-Looking Statements Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company" or "Alkermes") expectations with respect to its current and future financial and operating performance, business plans or p ...

Extraordinary Care That Changes Lives Option Care Health, Inc. 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 © 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED 1 Disclaimers Forward-Looking Statements This presentation may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estim ...

44th Annual J.P. Morgan Healthcare Conference 2026 Breakthrough Therapies Driving Accelerating Growth Brett Monia, Ph.D. Chief Executive Officer January 2026 | Nasdaq: IONS Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement desc ...

Financial Performance - 2025 - Revenue reached $2008 billion, up 8% year-over-year[5, 27] - Pre-tax income increased to $71 billion, a 21% increase year-over-year[5, 27] - Net income was $53 billion, up 22% year-over-year[5, 27] - EPS increased by 28% to $740, or 24% excluding notable items[5] - The ROTCE was 261%, up 33%-pts year-over-year[5] Q4 2025 Financial Highlights - Revenue increased by 7% year-over-year to $5179 billion[24, 25] - Expenses increased by 4% year-over-year, excluding notable items[24] - Adjusted pre-tax margin was 37%, up 3%-pts year-over-year[24] - EPS increased by 31% year-over-year to $202, or 21% excluding notable items[24] Strategic Initiatives & Efficiency - Efficiency savings of approximately $550 million were generated[6] - Approximately $500 million was invested in new client solutions, technology, and personnel[6] - Operating leverage was 507 bps for the full year[3, 27] - The company returned $14 billion to common shareholders, including $377 million in dividends and $10 billion in share repurchases[24] Segment Performance - 2025 - Securities Services total revenue was $97 billion, up 9% year-over-year[67] - Market and Wealth Services total revenue was $70 billion, up 12% year-over-year[71] - Investment and Wealth Management total revenue was $33 billion, down 4% year-over-year[75] Outlook - The company aims to deliver its fourth consecutive year of positive operating leverage in 2026, targeting over 100 bps[56, 57] - Revenue is expected to increase by 5% year-over-year[57]

4Q25 Financial Highlights - 4Q25 net income was $13 billion, with an EPS of $4.63[4] - Managed revenue reached $46.8 billion[4] - Expenses amounted to $24 billion, resulting in a managed overhead ratio of 51%[4] - Average loans stood at $1.5 trillion, up 9% year-over-year and 3% quarter-over-quarter[4] - Average deposits totaled $2.6 trillion, reflecting a 6% increase year-over-year and a 2% increase quarter-over-quarter[4] FY25 Financial Highlights - FY25 net income was $57 billion, down 2% year-over-year[8] - Managed revenue reached $185.6 billion, up 3% year-over-year[9] - Expenses amounted to $95.6 billion, up 4% year-over-year[9] - Credit costs were $14.2 billion[9] 2026 Outlook - The company expects approximately $95 billion in Net Interest Income (NII) excluding Markets for 2026[44] - The company projects adjusted expenses of approximately $105 billion for 2026[47]

Needham Growth Conference January 13, 2026 Nasdaq: ATRO Peter J. Gundermann, Chairman, President & CEO Nancy L. Hedges, Vice President & CFO astronics.com Safe Harbor Statement This presentation contains forward-looking statements as defined by the Securities Exchange Act of 1934. One can identify these forward-looking statements by the use of the words "expect," "anticipate," "plan," "may," "will," "estimate," "feeling" or other similar expressions and include all statements with regard to the Company's pr ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：1661） (1)董事會組成變動；及 (2)董事委員會組成變動 中國前沿科技集團（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，(i) 常海松 先生（「常先生」）已不再擔任執行董事；(ii) 吳明聰先生（「吳先生」）已不再擔任獨 立非執行董事及審核委員會成員；及(iii) 彭小留女士（「彭女士」）已獲委任為審核 委員會成員，均自2026年1月13日起生效。 董事會組成變動 常先生因工作安排變更而辭任執行董事，及吳先生為投入其他工作及業務承擔而 辭任獨立非執行董事，均自2026年1月13日起生效。常先生及吳先生均已向董事會 確認，就彼等的辭任而言：(i)概無針對本公司的申索；(ii)與董事會並無意見分歧； 及(iii)概無需提請聯交所或本公司股東垂注的事宜。 董事會謹藉此機會就常先生及吳先生於任期內為本公司所作的寶貴貢獻表示衷心 感謝。 董事委員會組成變動 吳先生辭任獨立非執行董事後， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示概不就因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE OILSANDS LTD. 陽光油砂有限公司* （一家根據加拿大阿爾伯塔省商業公司法註冊成立的有限公司） （香港聯交所：2012） 更換首席執行官 本公告由陽光油砂有限公司（「本公司」或「陽光」，及其附屬公司統稱「本集團」）根據香港 聯合交易所有限公司證券上市規則（「上市規則」）第 13.51(2)條而作出。 本公司之董事會（「董事會」）僅此宣佈，本公司首席執行官（「首席執行官」）職位出現以下 變動。 孫建平先生(「孫先生」)由於其他工作需要他奉獻更多時間，將離任首席執行官職位，自二零二 六年一月十三日起生效。 孫先生已確認，彼與董事會及本公司並無意分歧，亦無其他有關其離任首席執行官之事宜須提請 本公司股東（「股東」）和香港聯合交易所有限公司垂注。 委任首席執行官 董事會宣佈，Doug Brown, P. Eng 先生(「Brown 先生」)，已獲委任為首席執行官，自二零二六 年一月十三日 ...